Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 5/20 | 0.47 |
| ▸ | RHOA | P61586 | 5/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22446348 | 0.87 | RHOC (0.54) | RHOCRHOAEPHX2TP53BP1P2RX1 | |
| SCHEMBL22446314 | 0.85 | RHOC (0.45) | RHOCRHOATGM2EPHX2TP53BP1 | |
| SCHEMBL18763027 | 0.84 | RHOC (0.44) | RHOCRHOATGM2EPHX2TP53BP1 | |
| SCHEMBL23256742 | 0.84 | RHOC (0.47) | RHOCRHOATGM2EPHX2TP53BP1 | |
| SCHEMBL23257556 | 0.83 | TGM2 (0.50) | RHOCRHOATGM2P2RX1BCHE | |
| SCHEMBL23257554 | 0.78 | TGM2 (0.45) | RHOCRHOATGM2P2RX1BCHE | |
| SCHEMBL23257559 | 0.78 | TGM2 (0.43) | RHOCRHOATGM2P2RX1BCHE | |
| SCHEMBL23256741 | 0.77 | MEN1 (0.57) | TGM2 | |
| SCHEMBL18763049 | 0.76 | TGM2 (0.69) | TGM2P2RX1ALDH1A1TACR1 | |
| SCHEMBL20857042 | 0.76 | P2RX1 (0.62) | RHOCRHOATGM2P2RX1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | RHOC 1842/4885RHOA 3545/4885TGM2 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.